Long-term treatment with eribulin in heavily pretreated women with metastatic breast cancer: a case series. (April 2017)

• Record Type: Journal Article
• Authors: Morritti, Maria; Iodice, Giuseppe; Melaccio, Assunta; D'Onofrio, Loretta; Bergnolo, Paola; Boglione, Antonella; Comandone, Alessandro; Molinaro, Peppina; Garigliano, Danula
• Is Part Of: Future oncology. Volume 13(2017)Supplement 11
• Page Start: 25
• Page End: 33
• Publication Date: 2017-04
• Subjects: chemotherapy -- eribulin -- line of treatment -- metastatic breast cancer -- progression-free survival; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2016-0529
• Languages: English
• ISSNs: 1479-6694

Abstract

During the last decades, much effort has been made to develop and test treatments for advanced/metastatic breast cancer (MBC) able to prolong survival and improve patients' quality of life. In this regard, eribulin represents one of the most recent and interesting discoveries. This tubulin-targeting chemotherapy demonstrated a survival benefit in MBC women who progressed after at least two prior lines of chemotherapy for the treatment of metastatic disease (prior therapies should have included an anthracycline and a taxane, in either adjuvant or metastatic setting). Here, we described five cases of heavily pretreated MBC patients who experienced long-lasting control of disease with eribulin.